Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Publisher: John Wiley & Sons Inc

E-ISSN: 1552-4957|94|1|100-111

ISSN: 1552-4949

Source: Cytometry. Part B: Clinical Cytometry, Vol.94, Iss.1, 2018-01, pp. : 100-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract